Method for suppressing the acute phase response in a patient rec

Details Method for suppressing the acute phase response in a patient rec Method for suppressing the acute phase response in a patient rec

1993-12-13

1997-02-04

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Lymphokine

424 852, A61K 4505

Patent

active

055995365

ABSTRACT:
A method for ameliorating or suppressing the acute phase response in a patient receiving IL-6 treatment comprises co-administering with the IL-6 an effective amount of granulocyte colony stimulating factor.

REFERENCES:
patent: 5171840 (1992-12-01), Kishimoto
patent: 5178856 (1993-01-01), Burstein
patent: 5188828 (1993-02-01), Goldberg et al.
patent: 5299496 (1993-07-01), Deepey et al.
Akira et al., "A Nuclear Factor for IL-6 Expression (NF-IL6) is a Member of a C/EBP Family," EMBO J. (1990 Jun.) 9 (6) 1897-1906.
Akira et al., "IL-6 and NF-IL6 in Acute Phase Response and Viral Infection," Immunol. Rev., (1992 Jun.) 127, 25-50.
Akira et al., "Interleukin-6 in Biology and Medicine," Adv. Immunol., (1993) 54, pp. 22-27.
Andus et al., "Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-B2) regulates B-fibrinogen and albumin mRNA levels in Fao-9 Cells," FEBS Lett. 221:18 (1987).
Bataille et al., "Cytokines et Proliferations Lymphoplasmocytaires: Role Essential de L'Interleukine 6", Rev Prat (Paris) 1993, 43, 3, pp. 275-278.
Caracciolo et al., "Human Interleukin-6 Supports Granulocytic Differentiation of Hematopoietic Progenitor Cells and Acts Synergistically with GM-CSF", Blood, vol. 73, No. 3, (Feb. 15), 1989: 666-670.
Castell et al., "Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes," FEBS Lett. 232:347 (1988).
Castell et al., "Interleukin-6. The Major Regulator of Acute-Phase Protein Synthesis in Man and Rat," 1989. Ann. N.Y. Acad. Sci., 557: 87-101.
Chang et al., "Phase I Study of Interleukin-6 (IL-6) in Cancer Patients Treated with Ifosfamide, Carboplatin, and Etoposide (Ice)," Blood, 80, 1992 (No. 10, Suppl. 1) Abs. 346.
Demetri et al., "Recombinant Human Interleukin-6 (IL-6) Increases Circulating Platelet Counts and C-Reactive Protein Levels In Vivo: Initial Results of a Phase I Trial in Sarcoma Patients with Normal Hemopoiesis," Blood, 80, 1992, (No. 10, Suppl. 1) Abs. 344.
Fay et al., "Concomitant Administration of Interleukin-6 (rH IL-6) and Leucomax (rh GM-SCF) Following Autologous Bone Marrow Transplantation-A Phase I Trial," Blood 1993, vol. 82, (10, Suppl. 1), p. 431a (abs. 1707).
Gasparetto et al., "Dyshematopoiesis in Combined Immune Deficiency with Congenital Neutropenia," Am. J. Hematol., (1994) 45/1 (63-72).
Gauldie et al., "Interferon B.sub.2 /B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells," PNAS USA 84: 7251 (1987).
Geiger et al., "Induction of rat acute phase proteins by interleukin 6 in vivo," Eur. J. Immunol. 18: 717 (1988).
Harousseau et al., "Phase I/II trial of recombinant human IL-6 and GM-CSF following autologous bone marrow transplantation for non-Hodgkin's lymphoma," EBMT, Mar. 13, 1994 Harrowgate Meeting.
Heinrich et al., "Interleukin-6 and the acute phase response," Biochem. J. (1990) 265, 621-636.
Iguchi et al., "Effect of Recombinant Human Granulocyte Colony-Stimulating Factor Administration in Normal and Experimentally Infected Newborn Rats," Exp Hematol., (1991 Jun.) 19 (5), pp. 352-358.
Klein et al., "Interleukine 6 et myelome multiple chez l'homme" medicine/sciences 1991; 7: 937-43.
Kushner et al., "Acute Phase Proteins as Disease Markers," in Disease Markers, vol. 5, 1-11 (1987).
MacVittie et al., "Therapeutic Efficacy of rh IL-6 in a Nonhvman Primate Model of High Dose, Sublethal, Radiation-Induced Marrow Aplasia," Blood, 80, 1992, (No. 10, Suppl 1), Abs. 347.
McDonald, "The Regulation of Megakaryocyte and Platelet Production," in Concise Reviews in Clinical and Experimental Hematology, ed. M. Murphy, AlphaMed Press, Dayton, Ohio (1992) at 161-178.
Metsarinne et al., "Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus," Rheumatol Int. (1992) 12: 93-96.
Nijsten et al., "serum Levels of Interleukin-6 and Acute Phase Responses," Lancet ii:921 (1987).
Olencki et al., "Phase IA/IB Trial of rhIL-6 in Patients with Refractory Malignancy: Hematologic and Immunologic Effects," Blood, Nov. 15, 1992, vol. 80, No. 10, Suppl. 1 #344.
Patchen et al., "Administration of Interleukin-6 Stimulates Multilineage Hematopoiesis and Accelerates Recovery From Radiation-Induced Hematopoietic Depression," Blood, vol. 77, No. 3, (Feb. 1), 1991, pp. 472-480.
Patchen et al., "Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia," Experimental Hematology, 21: 338-344 (1993).
Pepys, "Acute Phase Proteins," in Encyclopedia of Immunology, Roiitt, I, ed., Academic Press (1992), 16-18.
Rennick et al., "Interleukin-6 Interacts with Interleukin-4 and Other Hematopoietic Growth factors to Selectively enhance the Growth of Megakaryocytic, Erythroid, Myeloid, and Multipotential Progenitor Cells," Blood, vol. 73, No. 7, (May 15), 1989, pp. 1828-1835.
Ryffel et al., "Pathology Induced by Interleukin-6," Toxicology Letters, 64/65, (1992) 311-319.
Sehgal, "Interleukin-6: Molecular Pathophysiology," J Invest Dermatol, 94 (Suppl): No. 6, pp. 2S-6S, (Jun. 1990).
Schipperus et al., "IL-6 enhances the GM-CSF induced in vitro colony formation of myelodysplastic marrow myeloid progenitor cells," Neth. J. Med., 37 (1990), p. A. 34.
Spronk et al., "Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity," Clin. exp. Immunol., (1992) 90, 106-110.
Stahl et al., "Effects of Human Interleukin-6 on Megakaryocyte Development and Thrombocytopoiesis in Primates," Blood, vol. 78, No. 6 (Sep. 15), 1991: pp. 1467-1475.
Swaak et al., "Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus," Rheumatol Int (1989) 8: 263-268.
Van Snick, "Interleukin-6: An Overview," Annu. Rev. Immunol. 1990, 8: 253-78.
Ballou et al Adv. in Intern. Med. vol. 37, pp. 313-336, (1992).
Mayer et al Exp. Hematol. 19: 688-696 (1991).
Tanikawa et al., Exp. Hematology, vol. 17, pp. 883-888, 1989.
Hamblin, "Cytokine and Cytokine Receptors," IRL Press, Chapter 4, 1993.
Aabrilove et al., J. Natl. Cancer Inst. Monogr., vol. 10, pp. 73-77, 1990.
Fibbe et al., Acta Haematol. (Basel), vol. 86(3), pp. 148-154, 1992.
Neta et al., Lymphokine Res., vol. 7(4), pp. 403-412, 1988.
Scheffner H., Allerg. Immunol., (Leipz.), vol. 36(2), pp. 77-86, 1990.
Akira et al., Adv. Immunol., vol. 54, pp. 1-78, 1993.

Affiliated with

Also associated with

Rating

Method for suppressing the acute phase response in a patient rec does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for suppressing the acute phase response in a patient rec, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for suppressing the acute phase response in a patient rec will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-676065